Current Price: 243.04 Direction: LONG Confidence level: 62%(Professional trader commentary suggests upside movement in the next 1–2 weeks, X sentiment leans bullish, and technical indicators show price above multiple moving averages indicating trend continuation.) Targets Target 1: 249.00 Target 2: 255.00 Stop Levels Stop 1: 238.00 Stop 2: 234.00 Wisdom of Professional Traders: This analysis synthesizes insights from thousands of professional traders and market experts, combining what traders are saying across professional analysis and real‑time social sentiment. The wisdom of crowds principle suggests that when many experienced traders highlight similar momentum patterns, it often reveals opportunities that individual analysis can miss. Key Insights: Here’s what’s driving this setup. Several professional traders pointed out that Johnson & Johnson could see “good moves in the next one to two weeks,” which tells me the trading community is watching for short‑term upside rather than downside pressure. That kind of language usually shows traders expecting momentum rather than a breakdown. At the same time, social sentiment on X leans bullish. Most trading‑related posts highlight the stock’s stability, dividend attractiveness, and pipeline developments. When defensive healthcare names attract positive chatter during a steady market environment, it often means investors are positioning for gradual upside rather than chasing high‑beta tech. The technical backdrop also supports the bullish case. JNJ is trading above its 5‑day, 10‑day, 20‑day, and 60‑day moving averages. When a stock sits above that entire stack of averages, traders usually interpret it as trend continuation rather than exhaustion. Recent Performance: JNJ has been grinding higher inside a steady upward channel. The stock recently traded around $243 after bouncing off the $240 pivot zone. Over the past few weeks it has consistently respected higher lows, which tells me buyers keep stepping in during dips. Volume has remained stable around the 7M share range, suggesting institutional participation rather than retail‑driven spikes. Expert Analysis: Several professional traders highlighted the expectation of a near‑term move in the coming week or two. That aligns well with the technical structure: the stock is approaching resistance around the $247–$250 region while momentum indicators like MACD remain positive. What caught my attention is how strong the long‑term trend looks. The 200‑day moving average sits far lower around the $198 area, meaning the broader trend has been firmly upward for months. When price is this extended above long‑term support but still grinding upward instead of reversing, it often means institutional buyers are accumulating gradually. News Impact: Recent developments in JNJ’s pharmaceutical pipeline are helping sentiment. The fast‑track designation for the drug nipocalimab has created optimism around future revenue potential in immunology. Analysts have also issued price targets around $250, which conveniently aligns with the immediate technical resistance traders are watching. The market also sees JNJ as a defensive large‑cap with a reliable dividend, so in uncertain macro conditions capital often rotates into names like this. Trading Recommendation: Here’s my take. The trader commentary, sentiment flow, and technical structure all lean toward continuation higher this week. I’d approach this with a LONG position near the current range around $243. The first upside test is $249 — that’s the area where sellers could appear. If momentum pushes through, the next move toward $255 becomes realistic within the week. Risk management matters here though: if price slips below $238 the short‑term structure weakens, and a deeper pullback toward $234 becomes possible. Position sizing should reflect the moderate conviction level — this isn’t an explosive breakout setup, but it does look like a steady trend continuation trade.

✅ Chart Analysis 1. Demand Zone Rejection Price pulled back perfectly into a well‑defined demand zone — this is where buyers previously stepped in aggressively. The reaction confirms strong institutional demand. 2. Trendline Break + Retest A descending trendline was broken, and price successfully retested the trendline from above, turning previous resistance into new support. This is a classic continuation signal. 3. EMAs Supporting the Trend Price is trading above the 50‑day EMA, showing short‑term strength. The 200‑day EMA is trending upward, confirming long‑term bullish structure. 4. Volume Behavior During the dip into the demand zone, volume remained controlled — a sign of absorption instead of panic selling. 5. Stochastic Indicator Stochastics curled upward from lower levels, supporting a momentum continuation. 📌 Technical Bias: Bullish as long as price holds above the demand zone ✅ Trade Idea Entry zone: Inside the demand/support area Stop‑loss: Place the stop‑loss below the demand zone, or adjust based on your personal capital allocation and risk tolerance. Take‑profit: Around $255–258, the previous swing structure ✅ Dividend Catalyst (Q2 2026) JNJ is a quarterly dividend stock, paying $1.30 per share as of 2026. According to verified dividend schedules: Next estimated Ex‑Date: May 27, 2026 Next estimated Payment Date: June 10, 2026 ✅ Summary JNJ is showing a clean bullish continuation setup after reacting at a strong demand zone, breaking the descending trendline, and holding above key EMAs. On the fundamentals side, the U.S. administration’s recent agreements with major pharma companies — including JNJ — provide regulatory clarity by introducing MFN drug pricing and tariff exemptions, helping stabilize sector sentiment. With an estimated next ex‑dividend date on May 27, 2026, dividend‑oriented accumulation may offer additional short‑term support. As long as price holds above the demand zone, the bullish outlook toward the $255–258 range remains intact.

Based on the recent pharma agreements reported by Reuters — where 16 global drugmakers committed to lower U.S. prices in exchange for tariff exemptions — overall sector sentiment appears stable. Technically, price is reacting well within the demand zone, retesting structure and holding above key moving averages. This improves the probability of upside continuation but does not eliminate risk, especially given that FactCheck.org notes the long‑term impact of these agreements is still uncertain.

✅ ENTRY RANGE Anywhere near current price or on a dip to support. ✅ TARGET $255–$260 in 3–4 months (~5–8% gain) ✅ STOP-LOSS (optional) Below recent swing low $216–$220 (Very unlikely to hit unless big market shock) ✅ RISK LEVEL Low JNJ is one of the most stable stocks you can swing trade.

Johnson & Johnson (JNJ) has been trading within a Channel Up since the 2008/09 U.S. Housing Crisis. This pattern has so far had four major correction events, technically its Bearish Legs, which on macro terms they are Bear Cycles. Its recent March 2026 High almost touched the top of this 18-year pattern and since the 1M RSI also hit the top of its multi-year Resistance Zone, it is technically very likely that the market is starting its new (5th) Bear Cycle. All previous ones broke below the 1W MA50 (blue trend-line), bottoming on at least the 0.382 Fibonacci retracement level from the last Low. On average, the total drop has been at least -20%. As a result, if the market has topped indeed, we expect this 2026 correction to target at least $205, which is slightly above the 0.382 Fib and -20% projected decline. At the same time, it would test the 0.5 Channel Fib, a trend-line that all previous corrections had hit. --- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** --- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇

Johnson & Johnson D1 - Remains in a bullish structure, holding above key support at 232.34. Current price action suggests strengthening momentum, with potential upside toward 256.98 and 263.69 as long as support is maintained. A break below 232.34 would weaken the bullish outlook.

Part of the ongoing S&P 500 Structural Census — a long-term structural observation of major U.S. equities. Structure assessed from earliest reliable data. Johnson & Johnson demonstrates a long-term secular advance supported by stable earnings and defensive business characteristics. The dominant regime remains impulsive, with price maintaining steady structural progression over multiple decades. Currently, price behaviour suggests continued higher-range progression within the long-term impulsive structure. Disclaimer This analysis is part of a long-term structural study and is not intended as trading or investment advice. #SP500Census #StructuralAnalysis #MarketStructure #JNJ #EwavesJournal

Johnson & Johnson (JNJ) is witnessing renewed demand following a retracement within a strong uptrend, characterized by a pattern of higher highs and higher lows with price trading above aligned moving averages. Against the backdrop of rising geopolitical tensions and increasing risks of a stagflationary environment, investors appear to be rotating into defensive sectors, strengthening the trend momentum in the healthcare space. Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products. The company operates through three primary segments: Consumer Health, Pharmaceutical, and Medical Devices. It has a market capitalization of approximately $587.32 billion. The company possesses a wide economic moat and has demonstrated consistent financial performance. Over the last four quarters, revenue has grown at an average rate of about 6%, while earnings per share (EPS) have increased by more than average NYSE:JNJ 53%. Profitability metrics remain strong, with return on equity (ROE), return on invested capital (ROIC), and net profit margin averaging above 30%, 20%, and 20%, respectively, during the same period. Johnson & Johnson also maintains a solid balance sheet, supported by adequate liquidity with a current ratio of around 1.0x and a conservative capital structure, reflected in a debt-to-equity ratio of approximately 0.6x. These fundamentals, combined with its defensive sector positioning, make the stock attractive during periods of heightened macroeconomic uncertainty.

Team, We are not buying now. Price is still trading below major descending resistance (R). As long as we are below R, the structure remains under pressure. ✅ What We Are Waiting For We only buy if: Price breaks above the descending resistance (R) A candle closes clearly above it We see strength (no immediate rejection wick) Ideally: a small pullback that holds above R No breakout = no trade. 🟢 Entry Plan (After Confirmation) Once price: Breaks above R Retests and holds

Johnson and Johnson is locked in a tug of war with the slimmest possible bullish edge. A high squeeze has been compressing for 8 bars with bearish momentum and the market is coiled for a directional move that could go either way. Price is at 242.58 with a -1.8% retrace and a 1% bounce at 0.5x expansion reading as partial recovery. Price percentile is 90.4% in the upper band of the 247.12 to 200 range. Despite the indecisive signals, price remains elevated near the top of its historical range. Bias is flat bull at 51.9% strength with a 27:25 signal split out of 112. This is essentially a coin flip. EMAs lean bullish at 7:4 and Ichimoku favors bulls at 9:4, providing the structural backbone for the slim bull edge. But candles tell the opposite story at 5:9 and counter-trend signals heavily favor bears at 6:8. DD/SS reads 11:0 and spread strength is just 3.8% confirming the flat indecisive nature. No star patterns, no harami, no three soldiers on either side. The squeeze is high and building for 8 bars with bandwidth compressed to 2.23%. Momentum is bearish and pointing down. Squeeze momentum is expanding downward at 474.5% which is significant. The compression is mature and the directional energy stored in this squeeze is substantial. Resolution should come soon. Volume is quiet at -0.82 Z on just 1.08K contracts and 261.99K in dollar terms. Direction reads neutral but momentum is decelerating sharply at -2.33, one of the steepest deceleration readings. Bull Z at -0.58 slightly trails bear Z at -0.42 suggesting mild selling pressure. OBV at 1.55 shows strong outflow with normal divergence. No whale activity detected. The combination of strong OBV outflow and decelerating momentum beneath a flat bias reading is quietly bearish. Distribution appears to be happening while price holds near the highs, which is a classic setup for a squeeze to resolve to the downside. Scenario 1 (45%) — Bullish resolution above 247.12 driven by the EMA and Ichimoku advantage. If the squeeze fires upward and volume breaks above the -0.82 baseline, the remaining gap to all-time territory is small. Defensive names like JNJ can attract flows in risk-off environments regardless of momentum readings. Scenario 2 (55%) — Bearish breakdown below the 238-240 area. The 5:9 candle count, 6:8 counter-trend lean, OBV outflow at 1.55, and 474.5% expanding downward squeeze momentum all favor the sellers. A volume pickup on a break lower would confirm that the distribution visible in OBV is transitioning to active selling. The 220-225 zone becomes the target. Watch for the squeeze to fire and which direction momentum resolves. OBV reversal from outflow to inflow would be the earliest bullish signal. A volume Z break below -1 on a down move would confirm the bearish case. The 8-bar compression is mature enough that the next few sessions should deliver the answer. Risk is moderate. The near-even signal split makes conviction trading difficult but the quiet distribution pattern beneath a flat surface gives bears the slight edge. Let the squeeze resolve before committing and use the 247.12 high and 238 support as directional triggers. More analysis on my profile. JNJ, Johnson, healthcare, pharma, squeeze, volume, momentum, equities